First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation After 2 weeks of induction ...

"Despite induction failure being 3-times more common in T-ALL than B-ALL, little was known about risk factors, optimum treatment, and the genomic landscape. If we can gain more understanding, we hope ...

ORLANDO, Florida ― The aggressive chemotherapy regimen given to children with acute lymphocytic leukemia (ALL) during the induction phase, which aims to push the disease into remission, also depletes ...

The U.S. Food and Drug Administration (FDA) approved mirikizumab, on October 26, 2023, a highly effective new treatment for ulcerative colitis (UC), offering a new option to patients battling this ...

Please provide your email address to receive an email when new articles are posted on . Significant improvements in clinical remission rates were observed at 12 weeks with risankizumab vs. placebo (20 ...

The study showed that having pre-existing leukopenia and more favorable performance status was associated with a higher risk of rash. Having a certain laboratory abnormality may be an indicator of ...

(WNDU) - There is a treatment helping patients return to normal after tongue cancer. Cancer, we all know it’s a tough battle for anyone diagnosed with it. The treatments can be brutal – chemo, ...